My Ultimate Sign-in System Made Me Invincible Chapter 466 Hands Are Tied (4) (Bonus Chapter)

The inaugural crisis board session kicked off merely twenty minutes after the announcement went public.

The drug firm's central offices spanned a full urban block in New Jersey, and the structure that usually cleared out by seven in the evening blazed with lights across every leadership level well past midnight. The top executive got yanked from a fundraising gala. The lead researcher, en route to London by air, got redirected in mid-journey. The others rushed in from residences, eateries, shows, or whatever spots late-night weekdays caught folks pulling in eight-digit incomes.

No one required details on the session's urgency. Everyone had witnessed it.

The finance chief jumped in first, as the monetary fallout proved simplest to measure, though toughest to swallow. 'Our market value plunged eleven percent during after-hours deals. That's $23 billion wiped from investor worth in just forty minutes. Come morning when exchanges reopen, anticipate at least another twenty to thirty percent slide.'

'Triggered by an announcement,' a voice noted. 'Unverified tech. Just words on a page.'

'Sparked by a reveal outlining tech that would wipe out our whole cancer unit, the bulk of our brain disorder lineup, and roughly sixty percent of our development pipeline.' The finance head's tone stayed even. 'Investors aren't pausing for evidence. They're factoring in the chance this holds truth, and that risk alone shreds our worth.'

The research director had scanned the press release on her device amid the talk. She glanced up. 'It's legitimate.'

Silence blanketed the chamber.

'You can't be certain,' the legal head countered.

'I can offer a solid judgment. Nova Technologies launched two innovations in four months. Each achieves feats beyond established science. Every one performs precisely as stated. They avoid boasts without backing. If they're unveiling healing nanites with such powers, I trust they possess healing nanites with such powers.'

'Assuming it's genuine,' the R&D leader added, 'trials demand years. Regulatory nods take years. We gain time to adjust.'

'They're launching tests off-planet in ninety days. They're skipping FDA clearance. They're not requesting approval. And they're streaming outcomes worldwide. By the point our standard reviews kick off, footage of wheelchair-bound folks striding and tumor victims healed will air everywhere. How do you figure that hits sales for our goods?'

No replies came.

The top executive, mute till then, bent ahead. 'Our choices. Practically speaking. What actions can we truly take?'

The strategy chief had evidently mulled this since the reveal hit. 'Tech rivalry is impossible. We lack anything near nanite-scale fixes and won't for decades, maybe never. Pricing competition fails—our top tumor therapies run hundreds of thousands yearly and just control illness, not erase it. Regulatory edges vanish since they're dodging that framework altogether.'

'Thus, no head-on counter.'

'Not directly. We shift to untouched zones. The reveal mentions ongoing lifespan extension work, so they lack it now. We target that. Plus preventive health, vitality enhancement, anything framing us as partners, not rivals.'

'That's a sliver of today's operations.'

'Correct. Hence the market slashed $23 billion from us tonight and likely another $50 billion by dawn.'

The legal advisor coughed lightly. 'Regulatory angles might exist. If we show their rollout poses health dangers or market dominance, we could chase lawsuits or push for shielding laws.'

'Shielding laws,' the executive echoed. 'Guarding drug makers from a breakthrough that heals ailments.'

'Safeguarding the medical network from chaos.'

'Imagine the public spin? 'Pharma giants battle to halt cancer fix over profit hits.' That's the front-page story. That's our congressional defense.'

'So what's your plan?'

The executive paused deeply. Then he voiced what no prior pharma board gathering in history would deem possible. 'We learn to collaborate with them, not clash. The other path leads to irrelevance, and I'd take scaled-back over vanished.'

The discussion dragged another three hours, yet that phrase set the course. Endurance via change, not resistance.

***

The insurer's response squad gathered with equal haste yet reached alternate verdicts via matching logic.

Before the formal huddle even launched, risk models got overhauled. All premises on death rates, illness spread, extended care expenses, and lifelong medical outlays recalibrated for worlds with widespread healing nanites.

The top risk expert shared initial insights that stirred unease in the space. 'In standard uptake cases—even twenty percent reach in five years—our life coverage turns outright unviable. Policies price off death charts expecting steady demises from expected ills. If those ills vanish, our whole cost structure crumbles.'

'And medical coverage?' a query rose.

'Grimmer. Coverage thrives on costly, erratic care. If nanites banish ongoing woes, block sudden sicknesses, and manage crises solo, what's left to cover? Routine exams and nanite fees? That's no insurance arena. That's billing facilitation.'

'What of impairment policies?'

'Maybe workable briefly, but with nanites rebuilding limbs and mending nerve harm, impairments turn fleeting, not lasting. Claim lengths shorten. Intensity fades. Rate rationale evaporates.'

The executive eyed the slides with intense gaze born of seeing a century-old framework dissolve live. 'This spells doomsday for all key offerings. What's our survival play?'

'Halting the tech is off-table. Regulation's weak—they sidestep usual paths. Rivalry fails; we're no med-tech outfit.' The strategy lead had pondered deeply. 'Yet we can cast ourselves as the money backbone enabling broad access.'

'Elaborate.'

'Sovereign Care runs $60,000 a year. That's reachable for top earners, not average households. We craft nanite access insurance lines. We bargain bulk deals for work-provided plans. We act as the bridge rendering the tech financially viable for masses.'

'We're covering entry to a tech rendering classic health plans obsolete.'

'Exactly. We embrace slimmer profits on fresh wares over fat ones on fading needs.'

The finance director tapped figures on his pad. 'The math stinks versus today. Earnings slices shrink dramatically.'

'Yet the potential market swells hugely. All crave nanites. Not all need old-school coverage post-nanites. We swap fat cuts from a contracting field for thin ones from an all-encompassing one.'

'That's no shift. That's total overhaul.'

'Indeed. Since sticking put means vanishing from a vanishing sector.'

The group took it in quietly.

The executive decided with the same weary nod as the drug board's. 'Prepare alliance drafts. Check Nova Technologies' interest in rollout ties. Probe work-group plan setups. And brace owners for the truth: we'll morph beyond recognition in five years.'

A voice raised what to inform staff, the hordes tied to a fading framework.

The executive lacked a solid reply.

***

The medical network's urgent leadership talk unfolded with milder alarm and greater readiness than business responses, perhaps as care deliverers had tracked Nova Technologies upending nearby fields for months and prepped for their hit.

The medical chief outlined fallout with sharp accuracy. 'Surgical wings turn mostly redundant. Cancer hubs fade away. Extended care sites empty of cases. Urgent care sees sharp drops if nanites auto-tackle crises.'

'We still handle nanite dosing,' a note sounded.

'One dose per individual, lifetime. We earn now via sustained therapies, repeat ops, enduring patient bonds. A single jab won't sustain a hospital network.'

'And those barred from the tech?'

'That group dwindles eventually. And aiding just the advanced-med excluded isn't expansion. It's controlled shrinkage.'

The finance head had crunched evening forecasts plainly. 'Two routes await. Cling to present services and see earnings tank as cases vanish. Or overhaul boldly toward prevention, vitality boosts, and acting as rollout hubs for nanites, while facing we're destined smaller.'

'By how much?'

'Forty to sixty percent cut in size over five to seven years. Possibly steeper if rollout speeds up.'

The executive scanned faces. 'Anyone spot a way to hold today's scale and ops?'

None could.

'So we chart controlled downsizing. Pinpoint closing sites, axed services, unsupported staff. And execute smart, not panicked.'

'That's thousands of roles.'

'True. But it's the truth. Face it now and strategize, or ignore and worsen the inevitable crash.'

The talk turned to tactics. Departments to trim. Sites to merge. Staff cuts to handle. Messaging to teams, cases, locales relying on them.

No joy in any choice. Yet all saw value in adapting unhappily over reveling into obscurity.

***

The investment group's partner huddle buzzed with distinct vibe.

As drug and coverage firms tallied hits, the backers eyed gains. The big display ran forecasts assuming healing nanites delivered as promised and built outward.

'Medicine claims $4 trillion yearly in U.S. outlays, near $10 trillion worldwide. Nova Technologies grabs a hefty share soon. But not the lot. Side fields emerge. Support roles. Support systems. That's our stakeout spot.'

The lead partner edged in. 'Concrete chances.'

'Nanite fee funding for buyers short on initial cash. Vitality services syncing with nanite scans. Health data insights from nanite logs. Travel setups for folks heading to dosing sites. Advice on rules for places reshaping med systems.'

'All hinge on Nova Technologies sticking to their path. What if they consolidate and snag those sides?'

'Then those bets flop. But the core holds: Earth's biggest sector restructures fully. That births chances. We skip clashing with Nova Technologies. We hunt gaps they skip and erect there.'

A partner fetched holdings review. 'Our med stakes suffer badly. Three tied to drugs. Two to devices. All five confront dooms.'

'We mark them down and redirect funds to winners in the fresh terrain, not losers. That's our way. No tears for shakeups. We cash in.'

'Even if shakeups kill our holdings?'

'Most so. Early jumps to new tides trump fidelity to old waves.'

The outfit started outlining bets for nanite-era medicine. Parts of today's holdings perish. But smart spots in the rising web promise yields dwarfing old med yields.

That's funding life. Detached, chance-grabbing, forever chasing lopsided edges.

***

In every field the reveals grazed, like talks echoed with varied outcomes driven by unique motives.

Movie houses called urgent tactic meets to rival Lucid Studio as shares fell fifteen to twenty percent in hours. Stream platforms gauged if their archives held worth when Lucid users spawned rival content solo. Gear makers for production confronted gear soon useless for content tiers.

Some picked bold shifts. Some defensive stances. Some rejected the change's reach, betting on market hype.

Yet in all sectors, all chambers, all plans, one truth dawned: Nova Technologies birthed tech not vying with markets. It supplanted them. Supplanting brooks no rivalry. Just shift or fade.

Survivors would be quickest to embrace truth and reshape fully. Fighters clinging to bygone models just delayed demise.

By dawn's market open, near $800 billion in worth vanished from med and fun sectors. Pundits deemed it excess. Leaders from night's crisis talks knew it likely understated.

The remake launched. Years to finish. But the path shone clear.

Shift or fade. Sole paths left.